Building 4
Suite 200 3000 El Camino Real
Palo Alto, CA 94306
United States
650 507 0669
https://180lifesciences.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 4
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder & Executive Chairman | 168,75k | N/D | 1948 |
Dr. James N. Woody M.D., Ph.D. | CEO & Director | 617,77k | N/D | 1942 |
Mr. Ozan Pamir C.F.A. | CFO & Secretary | 410,24k | N/D | 1992 |
Dr. Jonathan B. Rothbard Ph.D. | Chief Scientific Officer | 260,34k | N/D | 1953 |
Prof. Jagdeep Nanchahal | Co-Founder & Chairman of Clinical Advisory Board | N/D | N/D | N/D |
Mr. Jason Assad | Director of IR | N/D | N/D | N/D |
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Palo Alto, California.
L'ISS Governance QualityScore di 180 Life Sciences Corp. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.